Form DEFA14A EKSO BIONICS HOLDINGS,
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934
Filed by the Registrant ☑
Filed by a Party other than the Registrant
Check the appropriate box:
Preliminary Proxy Statement | |||||
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | |||||
Definitive Proxy Statement | |||||
☑ | Definitive Additional Materials | ||||
Soliciting Material Under § 240.14a-12 |
Ekso Bionics Holdings, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant) |
Payment of Filing Fee (Check the appropriate box):
☑ | No fee required | |||||||
Fee paid previously with preliminary materials. | ||||||||
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ekso Bionics to Report First Quarter 2024 Financial Results on April 29, 2024
- Wearable Medical Devices Market Experiences 25.7% CAGR, Surpassing USD 210 Billion by 2031, Driven by Rising Chronic Diseases and Focus on Preventive Care
- Healthcare Supply Chain Management Market to Hit USD 10.14 Billion by 2031, Driven by Technological Advancements & Rising Focus on Cost Efficiency
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!